Akram AbawiI; Anders MagnusonII; Ole FröbertIII; Ninos SamanoIV
DOI: 10.21470/1678-9741-2022-0461
ABSTRACT
Introduction: There is no consensus on the impact of coronary artery disease in patients undergoing transcatheter aortic valve implantation. Therefore, the objective of this study was, in a single-center setting, to evaluate the five-year outcome of transcatheter aortic valve implantation patients with or without coronary artery disease.AS = Aortic stenosis
AVR = Aortic valve replacement
BAV = Balloon aortic valvuloplasty
CABG = Coronary artery bypass grafting
CAD = Coronary artery disease
CI = Confidence interval
CLD = Chronic lung disease
DB = Diagonal branch
eGFR = Estimated glomerular filtration rate
EuroSCORE = European System for Cardiac Operative Risk Evaluation
FRANCE-2 = FRench Aortic National CoreValve and Edwards
HR = Hazard ratio
LVEF = Left ventricular ejection fraction
NE = No estimate (because of sparse data)
NYHA = New York Heart Association
PAD = Peripheral arterial disease
PCI = Percutaneous coronary intervention
SD = Standard deviation
SWENTRY = Swedish Transcatheter Cardiac Intervention Registry
SYNTAX = SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
TAVI = Transcatheter aortic valve implantation
WHO = World Health Organization
INTRODUCTION
Severe aortic stenosis (AS) is a common condition among the elderly, with a prevalence of 3.4% in patients > 75 years old[1]. With medical treatment only, the condition carries a poor prognosis, with a reported three-year all-cause mortality reported at 57% by one study[2]. Surgical aortic valve replacement (AVR) was the only available treatment in the past and has been shown to be superior to medical therapy even in asymptomatic patients[3]. Since it was first performed by Alain Cribier in humans in 2002, transcatheter aortic valve implantation (TAVI) has become an established treatment for severe AS[4-7].
Coronary artery disease (CAD) and AS share similar associated clinical risk factors, such as older age, male sex, elevated lipoprotein levels, hypertension, and smoking[8,9]. The two conditions often concur, and CAD is prevalent in 30.8-78.2% of patients undergoing TAVI[10]. Patients with both severe AS and CAD undergoing surgical AVR have worse early and late survival compared with patients with severe AS alone[11]. The clinical impact of CAD in patients undergoing TAVI differs in previous reports. In a meta-analysis, Sankaramangalam et al.[10] (2017) found higher one-year mortality in patients with concomitant CAD, while data from the FRench Aortic National CoreValve and Edwards (FRANCE-2) registry showed similar death rates at a three-year follow-up[12]. Prior coronary artery bypass grafting (CABG) may unfavourably influence two-year outcome[13], while prior percutaneous coronary intervention (PCI) does not[14]. The aim of this study was to evaluate five-year survival in TAVI patients with or without CAD in a single-center setting.
METHODS
Study Design and Population
This retrospective observational study included all patients with severe AS undergoing TAVI between September 15, 2009, and November 29, 2019, at Örebro University Hospital (Örebro, Sweden). All included patients had intermediate to high surgical risk. Patients were divided into two groups according to the presence or absence of CAD. All patients underwent preoperative coronary angiography, except for a few cases where computed tomography angiography was performed. Patients with solitary stenosis or occlusion in a minor side branch were excluded from the study. Patients with spontaneous or iatrogenic coronary artery dissection were also excluded (Figure 1). The study was approved by the regional ethical review board (file number: 2019-06442).
Data Collection
Data were collected from patient files and the Swedish Transcatheter Cardiac Intervention Registry (SWENTRY), a sub-registry of the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (or SWEDEHEART). In the SWENTRY, all consecutive patients, from all centers in Sweden, undergoing TAVI are registered. Total follow-up time was defined as the date of the procedure to December 1, 2019. Electronic health records with direct linkage to survival status were used to document survival and cause of death. The primary endpoint, five-year all-cause mortality, was assessed using Cox regression adjusted for age, sex, procedure years, and comorbidities. Presence of comorbidities interacting with CAD, leading to increased five-year all-cause mortality, was evaluated with interaction tests. The secondary endpoint was in-hospital complications.
Statistical Analysis
Differences in continuous baseline characteristics between the CAD and non-CAD groups were tested with unpaired t-test, and ordinal scale characteristics with Mann-Whitney U test. Non-ordered categorical baseline characteristics and number of complications were analysed with chi-square test or Fisher’s exact test where appropriate. Unadjusted Kaplan-Meier and Cox regression analyses were used to visualize and evaluate time to mortality between the CAD and non-CAD groups. The patients were followed up until five years after the procedure, with no censored cases. Crude mortality rates per 1,000 person-years were presented, and adjusted Cox regression was performed in three models. The first model was adjusted for age in five-year categories (< 70, 70-74, 75-79, 80-84, and ≥ 85 years), sex, and procedure year as a categorical variable collapsing years 2009-2012 and 2013-2014 because of sparse data. The second model further adjusted for estimated glomerular filtration rate (eGFR) < 50 ml/min/1.73 m2, chronic lung disease (CLD), and pulmonary hypertension. The third model further adjusted for peripheral arterial disease (PAD) and left ventricular ejection fraction (LVEF) < 50%. The variables included in the three models were retrieved from the European System for Cardiac Operative Risk Evaluation (EuroSCORE). The purpose of dividing these variables into three models was to detect and eventually avoid over adjusting for risk factors. The potential effect modification of each adjusted variable described above on mortality, by CAD group, was evaluated with interaction tests. When non-proportional hazards were present, tested on the basis of Schoenfeld residuals, risk time was split at one year and time-dependent Cox regression was used. Cox regression gives hazard ratios (HRs) with 95% confidence intervals (CIs) as association measures. A P-value < 0.05 was regarded as statistically significant. All statistical computations were performed with STATA release 14 (StataCorp College Station, Texas, United States of America; www.stata.com) or IBM Corp. Released 2017, IBM SPSS Statistics for Windows, version 25.0, Armonk, NY: IBM Corp.
Definitions
CAD was defined as either the presence of a significant stenosis or occlusion in one or more coronary arteries or prior PCI and/or CABG, in line with the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial.
Vascular complications (major and minor) and stroke were defined according to the Valve Academic Research Consortium-2 (or VARC-2) consensus document.
The analysed comorbidities followed the categorization and definitions included in the EuroSCORE I risk model. Extracardiac arteriopathy is referred to as “peripheral arterial disease (PAD)” in our study.
RESULTS
In total, 176/346 (50.9%) patients had concomitant CAD and AS, while 170/346 (49.1%) had AS only. Prior PCI and/or CABG was performed in 151/346 (43.6%) patients, and 25 patients had CAD without prior coronary intervention. Baseline clinical characteristics are shown in Table 1. Significantly more patients in the CAD-AS group were males, and had PAD, a LVEF < 50%, hypertension, or a higher logistic EuroSCORE I. In the non-CAD group, more patients had CLD and elevated pulmonary artery pressure.
| Patients’ characteristics | CAD group (n=176) |
Non-CAD group (n=170) |
P-value |
|---|---|---|---|
| Age, years, mean (SD) | 80.5 (5.9) | 79.7 (7.5) | 0.23 |
| Men, n (%) | 103 (58.5) | 64 (37.6) | < 0.001 |
| Surgery year, n (%) | 0.015 | ||
| 2009-2012 | 28 (15.9) | 12 (7.1) | |
| 2013-2014 | 20 (11.4) | 22 (12.9) | |
| 2015 | 27 (15.3) | 12 (7.1) | |
| 2016 | 18 (10.2) | 21 (12.3) | |
| 2017 | 19 (10.8) | 23 (13.5) | |
| 2018 | 33 (18.8) | 34 (20.0) | |
| 2019 | 31 (17.6) | 46 (27.1) | |
| eGFR < 50, n (%) | 44 (25.0) | 34 (20.0) | 0.27 |
| CLD, n (%) | 20 (11.4) | 46 (27.1) | < 0.001 |
| Pulmonary hypertension, n (%) | n=157 | n=153 | 0.019 |
| ≤ 30 (normal) | 63 (40.1) | 41 (26.8) | |
| 31-55 | 76 (48.4) | 98 (64.0) | |
| > 55 | 18 (11.5) | 14 (9.2) | |
| PAD, n (%) | 39 (22.2) | 17 (10.0) | 0.002 |
| LVEF < 50%, n (%) | 59 (33.5) | 33 (19.4) | 0.003 |
| Body mass index, mean (SD) | 27.0 (5.7) | 27.1 (5.5) | 0.90 |
| Body mass index, WHO classification | 0.32 | ||
| < 18.5 (underweight), n (%) | 2 (1.1) | 7 (4.1) | |
| 18.5-24.9 (normal weight), n (%) | 71 (40.3) | 60 (35.3) | |
| 25.0-29.9 (pre-obesity), n (%) | 61 (34.7) | 56 (32.9) | |
| 30.0-34.9 (obesity class I), n (%) | 29 (16.5) | 36 (21.2) | |
| ≥ 35.0 (obesity class II or III), n (%) | 13 (7.4) | 11 (6.5) | |
| Smoking | n=159 | n=153 | 0.24 |
| Active smoker, n (%) | 14 (8.8) | 12 (7.8) | |
| Ex-smoker, n (%) | 76 (47.8) | 60 (39.2) | |
| Never smoked, n (%) | 69 (43.4) | 81 (52.9) | |
| Myocardial infarction ≤ 3 months, n (%) | 12 (6.8) | - | |
| Hypertension, n (%) | 154 (87.5) | 129 (75.9) | 0.005 |
| Diabetes, n (%) | 55 (31.2) | 46 (27.1) | 0.39 |
| Insulin, n (%) | 22 (12.5) | 20 (11.8) | 0.83 |
| Prior CABG, n (%) | 65 (36.9) | - | - |
| Prior PCI, n (%) | 107 (60.8) | - | - |
| Non-intervened CAD, n (%) | 25 (14.2) | - | - |
| Prior BAV, n (%) | 6 (3.4) | 2 (1.2) | 0.28 |
| Stroke, n (%) | 22 (12.5) | 18 (10.6) | 0.58 |
| Critical preoperative state, n (%) | 3 (1.7) | 4 (2.4) | 0.72 |
| Acute surgery, n (%) | 0 (0.0) | 0 (0.0) | - |
| Atrial fibrillation, n (%) | 62 (35.2) | 70 (41.2) | 0.26 |
| Dialysis, n (%) | 1 (0.6) | 3 (1.8) | 0.36 |
| NYHA function class III or IV, n (%) | 160 (90.9) | 150 (88.2) | 0.42 |
| Logistic EuroSCORE I | n=137 | n=138 | < 0.001 |
| mean % (SD) | 20.6 (14.2) | 13.7 (8.7) |
BAV=balloon aortic valvuloplasty; CABG=coronary artery bypass grafting; CLD=chronic lung disease; eGFR=estimated glomerular filtration rate; EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; PAD=peripheral arterial disease; PCI=percutaneous coronary intervention; SD=standard deviation; WHO=World Health Organization
In-Hospital Complications
In relation to the TAVI procedure, 25/176 (14.2%) and 18/170 (10.6%) patients experienced complications (vascular, new permanent pacemaker, stroke, or death) in the CAD and non-CAD groups, respectively (P=0.308).
Five-Year All-Cause Mortality and Cause of Death
The mean total follow-up time was 2.2±1.6 years. Among patients with surgery before December 1, 2014, with possible five-year follow-up, the all-cause mortality was 42/80 (52.5%); 23/48 (47.9%) in the CAD group and 19/32 (59.4%) in the non-CAD group. Cardiac death was numerically more common in the CAD group (13/23) than in the non-CAD group (8/19), but the difference was not statistically significant. Cause of death was missing in two patients in each group. A Kaplan-Meier curve illustrates the cumulative, unadjusted five-year survival in the CAD and non-CAD groups (Figure 2) in all 346 patients. Cox regression revealed no differences in five-year all-cause mortality between patients with and patients without CAD in the three different adjustment models (Table 2). In the third adjusted model, HR was 1.00 (95% CI 0.59-1.70), but patients with eGFR < 50 ml/min/1.73 m2 (HR 1.75 [95% CI 1.04-2.94]) and CLD (HR 2.20 [95% CI 1.26-3.84]) had a significantly increased mortality risk (Table 2).
| 0-60 months | n | Events | Rate | Model 1 | Model 2 | Model 3 |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| Non-CAD group | 170 | 43 | 10.8 | 1.0 | 1.0 | 1.0 |
| CAD group | 176 | 39 | 7.4 | 0.74 (0.46-1.20) | 1.02 (0.60-1.72) | 1.00 (0.59-1.70) |
| P=0.22 | P=0.95 | P=0.99 | ||||
| eGFR < 50 | ||||||
| No | 268 | 58 | 7.9 | 1.0 | 1.0 | 1.0 |
| Yes | 78 | 24 | 12.2 | 1.50 (0.92-2.43) | 1.78 (1.07-2.98) | 1.75 (1.04-2.94) |
| P=0.10 | P=0.027 | P=0.034 | ||||
| CLD | ||||||
| No | 280 | 56 | 7.5 | 1.0 | 1.0 | 1.0 |
| Yes | 66 | 26 | 14.6 | 2.00 (1.22-3.27) | 2.26 (1.31-3.90) | 2.20 (1.26-3.84) |
| P=0.006 | P=0.003 | P=0.006 | ||||
| Pulmonary hypertension | ||||||
| ≤ 30 (normal) | 104 | 19 | 6.5 | 1.0 | 1.0 | 1.0 |
| 31-55 | 174 | 44 | 9.8 | 1.37 (0.77-2.45) | 1.34 (0.74-2.40) | 1.30 (0.72-2.35) |
| P=0.29 | P=0.33 | P=0.38 | ||||
| > 55 | 32 | 11 | 10.9 | 1.27 (0.57-2.45) | 1.30 (0.58-2.90) | 1.21 (0.52-2.81) |
| P=0.56 | P=0.52 | P=0.66 | ||||
| PAD | ||||||
| No | 290 | 64 | 8.3 | 1.0 | 1.0 | |
| Yes | 56 | 18 | 11.5 | 1.18 (0.67-2.05) | 1.07 (0.56-2.08) | |
| P=0.57 | P=0.83 | |||||
| LVEF < 50% | ||||||
| No | 254 | 55 | 7.8 | 1.0 | 1.0 | |
| Yes | 92 | 27 | 11.9 | 1.58 (0.97-2.58) | 1.16 (0.66-2.03) | |
| P=0.063 | P=0.60 |
Events: Number of deaths
Rate: Crude number of deaths per 1,000 person-years
Model 1: Adjusted for age, sex, and year of surgery
Model 2: Adjusted for age, sex, year of surgery, eGFR < 50, chronic pulmonary disease, and pulmonary hypertension
Model 3: Adjusted for age, sex, year of surgery, eGFR < 50, chronic pulmonary disease, pulmonary hypertension, PAD, and LVEF < 50
CI=confidence interval; CLD=chronic lung disease; eGFR=estimated glomerular filtration rate; HR=hazard ratio; LVEF=left ventricular ejection fraction; PAD=peripheral arterial disease
Interaction Between Coronary Artery Disease and Comorbidities on Five-Year Mortality
Impaired renal function and presence of PAD showed a statistically significant interaction effect with CAD and mortality in all three adjusted models, with LVEF < 50% and age (≤ 79 vs. ≥ 80 years) only in the second and third adjusted models and with CLD only in the first adjusted model (Table 3, Figures 3 to 5, and Supplementary Figures 1 and 2).
| 0-60 months | n | Events | Rate | Model 1 | Model 2 | Model 3 |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| P-value | P-value | P-value | ||||
| CAD status combined with eGFR | ||||||
| Normal eGFR | ||||||
| Non-CAD group | 136 | 36 | 11.5 | 1.0 | 1.0 | 1.0 |
| CAD group | 132 | 22 | 5.2 | 0.48 (0.27-0.84) | 0.64 (0.34-1.20) | 0.62 (0.33-1.17) |
| P=0.010 | P=0.16 | P=0.14 | ||||
| eGFR < 50 | ||||||
| Non-CAD group | 34 | 7 | 8.1 | 1.0 | 1.0 | 1.0 |
| CAD group | 44 | 17 | 15.4 | 2.50 (0.98-6.41) | 2.88 (1.08-7.66) | 2.90 (1.09-7.77) |
| P=0.056 | P=0.034 | P=0.034 | ||||
| Interaction tests1 | P=0.002 | P=0.008 | P=0.007 | |||
| CAD status combined with CLD | ||||||
| No CLD | ||||||
| Non-CAD group | 124 | 27 | 9.9 | 1.0 | 1.0 | 1.0 |
| CAD group | 156 | 29 | 6.1 | 0.65 (0.37-1.13) | 0.78 (0.43-1.42) | 0.77 (0.42-1.40) |
| P=0.13 | P=0.42 | P=0.39 | ||||
| Presence of CLD | ||||||
| Non-CAD group | 46 | 16 | 12.7 | 1.0 | 1.0 | 1.0 |
| CAD group | 20 | 10 | 19.1 | 2.05 (0.87-4.84) | 1.97 (0.80-4.84) | 1.95 (0.80-4.78) |
| P=0.10 | P=0.14 | P=0.14 | ||||
| Interaction tests1 | P=0.027 | P=0.088 | P=0.083 | |||
| CAD status combined with PAD | ||||||
| No PAD | ||||||
| Non-CAD group | 153 | 38 | 11.0 | 1.0 | 1.0 | 1.0 |
| CAD group | 137 | 26 | 6.1 | 0.58 (0.34-0.98) | 0.72 (0.40-1.28) | 0.71 (0.39-1.27) |
| P=0.042 | P=0.26 | P=0.24 | ||||
| Presence of PAD | ||||||
| Non-CAD group | 17 | 5 | 9.6 | 1.0 | 1.0 | 1.0 |
| CAD group | 39 | 13 | 12.5 | 2.05 (0.68-6.21) | 6.02 (1.43-25.4)2 | 5.97 (1.41-25.2)2 |
| P=0.20 | P=0.0142 | P=0.0152 | ||||
| Interaction tests1 | P=0.031 | P=0.003 | P=0.003 | |||
| 1-year follow-up | ||||||
| No PAD | ||||||
| Non-CAD group | 153 | 12 | 8.2 | 1.0 | 1.0 | 1.0 |
| CAD group | 137 | 8 | 5.6 | 0.69 (0.28-1.71) | 0.77 (0.30-1.94) | 0.76 (0.30-1.92) |
| P=0.42 | P=0.58 | P=0.56 | ||||
| Patients with PAD | ||||||
| Non-CAD group | 17 | 1 | 5.7 | 1.0 | 1.0 | 1.0 |
| CAD group | 39 | 7 | 18.1 | 3.84 (0.46-31.9) P=0.21 |
NE | NE |
| CAD status combined with LVEF | ||||||
| Patients with LVEF ≥ 50% | ||||||
| Non-CAD group | 137 | 34 | 10.7 | 1.0 | 1.0 | 1.0 |
| CAD group | 117 | 21 | 5.5 | 0.57 (0.32-0.99) | 0.72 (0.38-1.35) | 0.71 (0.38-1.33) |
| P=0.049 | P=0.30 | P=0.28 | ||||
| Patients with LVEF < 50% | ||||||
| Non-CAD group | 33 | 9 | 11.0 | 1.0 | 1.0 | 1.0 |
| CAD group | 59 | 18 | 12.4 | 1.43 (0.60-3.39) | 2.21 (0.85-5.74) | 2.24 (0.86-5.85) |
| P=0.41 | P=0.10 | P=0.098 | ||||
| Interaction tests1 | P=0.061 | P=0.037 | P=0.034 | |||
| CAD status combined with age | ||||||
| < 80-year-old patients | ||||||
| Non-CAD group | 64 | 16 | 8.9 | 1.0 | 1.0 | 1.0 |
| CAD group | 63 | 16 | 8.9 | 1.02 (0.50-2.06)2 | 1.74 (0.80-3.76)2 | 1.78 (0.81-3.90)2 |
| P=0.972 | P=0.162 | P=0.152 | ||||
| ≥ 80-year-old patients | ||||||
| Non-CAD group | 106 | 27 | 12.3 | 1.0 | 1.0 | 1.0 |
| CAD group | 113 | 23 | 6.6 | 0.50 (0.28-0.89) | 0.58 (0.30-1.09) | 0.56 (0.30-1.07) |
| P=0.018 | P=0.093 | P=0.081 | ||||
| Interaction tests1 | P=0.12 | P=0.025 | P=0.021 | |||
| 1-year follow-up | ||||||
| < 80-year-old patients | ||||||
| Non-CAD group | 52 | 3 | 4.3 | 1.0 | 1.0 | 1.0 |
| CAD group | 53 | 9 | 14.1 | 3.15 (0.85-11.7) | 6.27 (1.33-29.6) | 6.19 (1.30-29.5) |
| P=0.086 | P=0.020 | P=0.022 | ||||
| ≥ 80-year-old patients | ||||||
| Non-CAD group | 73 | 19 | 10.6 | 1.0 | 1.0 | 1.0 |
| CAD group | 86 | 6 | 5.1 | 0.45 (0.16-1.26) | 0.44 (0.14-1.30) | 0.43 (0.14-1.28) |
| P=0.13 | P=0.14 | P=0.13 |
Events: Number of deaths
Rate: Crude number of deaths per 1,000 person-years
Model 1: Adjusted for age, sex, and year of surgery
Model 2: Adjusted for age, sex, year of surgery, eGFR < 50, chronic pulmonary disease, and pulmonary hypertension
Model 3: Adjusted for age, sex, year of surgery, eGFR < 50, chronic pulmonary disease, pulmonary hypertension, PAD, and LVEF < 50
1 Interaction tests were conducted if the CAD and non-CAD groups’ association with mortality was statistically significantly different in comorbidity and age sub-groups
2 Non-proportional hazards present at 5 years and 1 year were analysed
CI=confidence interval; CLD=chronic lung disease; eGFR=estimated glomerular filtration rate; HR=hazard ratio; LVEF=left ventricular ejection fraction; NE=no estimate (because of sparse data); PAD=peripheral arterial disease
Among patients with impaired renal function, the HR was 2.90 (95% CI 1.09-7.77) when comparing the CAD and non-CAD group in the third adjusted model. Among patients with PAD, the HR was 5.97 (95% CI 1.41-25.2); however, the hazard was non-proportional and because of few mortality cases it was not possible to evaluate only the first year of follow-up. Among patients with LVEF < 50%, the HR was 2.24 (95% CI 0.86-5.85) when comparing the CAD and non-CAD group. Among patients aged < 80 years, the HR was 1.78 (95% CI 0.81-3.90) but the hazard was non-proportional, and for the first year of follow-up, the HR was 6.19 (95% CI 1.30-29.5). Among patients with CLD, the HR was 1.95 (95% CI 0.80-4.78) (Table 3).
DISCUSSION
In this single-center observational study, we did not find differences in five-year mortality between patients with AS and CAD, and patients with AS alone undergoing TAVI. However, renal impairment, PAD, LVEF < 50%, and age ≥ 80 years in addition to CAD were associated with significantly higher five-year mortality.
The five-year all-cause mortality of 52.5% in our study is in line with previous studies reporting a mortality rate between 41.0% and 67.8%[4,15]. The proportion of CAD patients, 50.9%, is also consistent with a previously conducted meta-analysis[10]. At baseline, patients with CAD had a significantly higher logistic EuroSCORE I and more cardiovascular risk factors. Despite this, the CAD group had a similar five-year all-cause mortality.
Most previous studies investigating the impact of CAD on TAVI outcomes report follow-up times of no longer than three years. The populations and definitions of CAD in these studies have differed. Kawashima et al.[13] found that TAVI patients with previous CABG had a higher rate of two-year all-cause mortality and cardiovascular death. However, in their study, CAD was also present in the group without prior CABG. Results from the FRANCE-2 registry showed that CAD was not associated with increased mortality at 30 days or three years but the authors found that stenosis of the left anterior descending coronary artery was associated with higher three-year mortality[12]. One important factor to note is that patients with prior CABG were excluded from their study, which may explain why the prevalence of CAD was lower, at 36%. Two meta-analyses on the subject reached different conclusions: Sankaramangalam et al.[10] in 2017 studied the impact of CAD (n=3,899) in patients (n=8,013) undergoing a TAVI procedure and showed that the CAD group had a significantly lower survival at one year. In the same year, Kotronias et al.[14] investigated the effect of previous PCI (n=983) vs. no previous PCI in TAVI patients (n=3,858) on one-year all-cause mortality. They found no differences between groups.
In one study, impaired renal function (eGFR < 30 ml/min/1.73 m2) was associated with increased one-year mortality after TAVI[16]. In another report, impaired renal function with eGFR < 60 ml/min/1.73 m2 was not associated with increased death rates at one year after TAVI[17]. Impaired renal function in our study (eGFR < 50 ml/min/1.73 m2) was not associated with increased five-year mortality but the interaction between CAD and impaired renal failure was significant and associated with higher five-year mortality.
The total prevalence of PAD was 22.1% and 10.0% in the CAD and non-CAD groups, respectively. This is in line with previous studies reporting a prevalence of 19.2-25.1%[18,19]. PAD has been associated with increased early (< 30 days) and late (> 12 months) mortality after TAVI[18,20]. Such association was only seen when the interaction between PAD and CAD was analysed in our study. There were more patients with PAD in the CAD than in the non-CAD group, which was unsurprising given the overlap of risk factors.
Pulmonary hypertension and impaired LVEF in patients with AS are common indicators of advanced disease usually resulting in poor prognosis[21,22]. Contradicting other reports[21,23], in our study neither of these comorbidities alone had an impact on five-year mortality. CLD was the only isolated comorbidity associated with higher five-year mortality after TAVI. This finding is supported by previous studies[24] and may prove helpful in future patient selection.
Until recently, and before the publication of the low-risk TAVI trials[6,7], TAVI was mainly reserved for elderly patients with intermediate or high operative risk. With this in mind, we studied the interaction between CAD and age ≥ 80 years and found higher five-year mortality. Our study is a small contribution to the current evidence gap of TAVI patients with CAD and is in line with an ongoing trial - the COMPLETE TAVR (ClinicalTrials.gov: NCT04634240). Additionally, our data shows similar results as the newly published study from the percutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantation (or ACTIVATION) trial; similar observed rates of death and rehospitalizations at 1 year between PCI and no PCI prior to TAVI[25], albeit their time frame of one year differs from our five years.
Limitations
There is a risk for bias in this observational study, mainly due to the selection and classification of patients, potential confounding factors not accounted for in our analysis in addition to bias for missing data. Missing data in the registry were addressed through reviewing and adding data from the individual patient’s electronic health records. However, not all missing data were accounted for using this method. As this was a single-center study, the number of participants was relatively small, and the number of patients having a follow-up of five years or longer was limited to a total of 80 patients. Unfortunately, SYNTAX score was not registered for all the TAVI patients with CAD.
REFERENCES
1. Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReunCM, et al. Aortic stenosis in the elderly: disease prevalence and number ofcandidates for transcatheter aortic valve replacement: a meta-analysis andmodeling study. J Am Coll Cardiol. 2013;62(11):1002-12.doi:10.1016/j.jacc.2013.05.015. [MedLine]
2. Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aorticstenosis in adults. Am Heart J. 1980;99(4):419-24.doi:10.1016/0002-8703(80)90375-0. [MedLine]
3. Campo J, Tsoris A, Kruse J, Karim A, Andrei AC, Liu M, et al.Prognosis of severe asymptomatic aortic stenosis with and without surgery. AnnThorac Surg. 2019;108(1):74-9.doi:10.1016/j.athoracsur.2019.01.031. [MedLine]
4. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al.5-year outcomes of transcatheter aortic valve replacement or surgical aorticvalve replacement for high surgical risk patients with aortic stenosis (PARTNER1): a randomised controlled trial. Lancet. 2015;385(9986):2477-84.doi:10.1016/S0140-6736(15)60308-7. [MedLine]
5. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, etal. Transcatheter or surgical aortic-valve replacement in intermediate-riskpatients. N Engl J Med. 2016;374(17):1609-20.doi:10.1056/NEJMoa1514616. [MedLine]
6. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al.Transcatheter aortic-valve replacement with a balloon-expandable valve inlow-risk patients. N Engl J Med. 2019;380(18):1695-705.doi:10.1056/NEJMoa1814052. [MedLine]
7. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al.Transcatheter aortic-valve replacement with a self-expanding valve in low-riskpatients. N Engl J Med. 2019;380(18):1706-15.doi:10.1056/NEJMoa1816885. [MedLine]
8. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, SmithVE, et al. Clinical factors associated with calcific aortic valve disease.Cardiovascular Health Study. J Am Coll Cardiol. 1997;29(3):630-4.doi:10.1016/s0735-1097(96)00563-3. [MedLine]
9. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Developmentand progression of aortic valve stenosis: atherosclerosis risk factors--a causalrelationship? A clinical morphologic study. Clin Cardiol. 1991;14(12):995-9.doi:10.1002/clc.4960141210. [MedLine]
10. Sankaramangalam K, Banerjee K, Kandregula K, Mohananey D, Parashar A, Jones BM, et al. Impact of coronary artery disease on 30-day and 1-year mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis. J Am Heart Assoc. 2017;6(10):e006092. doi:10.1161/JAHA.117.006092.
11. Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2013;61(8):837-48. doi:10.1016/j.jacc.2012.10.049.
12. Puymirat E, Didier R, Eltchaninoff H, Lung B, Collet JP, Himbert D, et al. Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: insights from the FRANCE-2 registry. Clin Cardiol. 2017;40(12):1316-22. doi:10.1002/clc.22830.
13. Kawashima H, Watanabe Y, Kozuma K, Kataoka A, Nakashima M, Hioki H, et al. Comparison of midterm outcomes of transcatheter aortic valve implantation in patients with and without previous coronary artery bypass grafting. Heart Vessels. 2018;33(10):1229-37. doi:10.1007/ s00380-018-1166-9.
14. Kotronias RA, Kwok CS, George S, Capodanno D, Ludman PF, Townend JN, et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(6):e005960. doi:10.1161/JAHA.117.005960.
15. Ben-Shoshan J, Zahler D, Margolis G, Arbel Y, Konigstein M, Chorin E, et al. Relation of clinical presentation of aortic stenosis and survival following transcatheter aortic valve implantation. Am J Cardiol. 2019;123(6):961-6. doi:10.1016/j.amjcard.2018.12.009.
16. Levi A, Codner P, Masalha A, Gargiulo G, Praz F, Hayashida K, et al. Predictors of 1-year mortality after transcatheter aortic valve implantation in patients with and without advanced chronic kidney disease. Am J Cardiol. 2017;120(11):2025-30. doi:10.1016/j. amjcard.2017.08.020.
17. Rahman MS, Sharma R, Brecker SJD. Transcatheter aortic valve implantation in patients with pre-existing chronic kidney disease. Int J Cardiol Heart Vasc. 2015;8:9-18. doi:10.1016/j.ijcha.2015.04.006.
18. Kim BG, Ko YG, Hong SJ, Ahn CM, Kim JS, Kim BK, et al. Impact of peripheral artery disease on early and late outcomes of transcatheter aortic valve implantation in patients with severe aortic valve stenosis. Int J Cardiol. 2018;255:206-11. doi:10.1016/j.ijcard.2017.11.065.
19. Sinning JM, Horack M, Grube E, Gerckens U, Erbel R, Eggebrecht H, et al. The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation: results from the German transcatheter aortic valve interventions registry. Am Heart J. 2012;164(1):102-10.e1. doi:10.1016/j.ahj.2012.04.016.
20. Ueshima D, Barioli A, Nai Fovino L, D'Amico G, Fabris T, Brener SJ, et al. The impact of pre-existing peripheral artery disease on transcatheter aortic valve implantation outcomes: a systematic review and metaanalysis. Catheter Cardiovasc Interv. 2020;95(5):993-1000. doi:10.1002/ ccd.28335.
21. Kokkinidis DG, Papanastasiou CA, Jonnalagadda AK, Oikonomou EK, Theochari CA, Palaiodimos L, et al. The predictive value of baseline pulmonary hypertension in early and long term cardiac and all-cause mortality after transcatheter aortic valve implantation for patients with severe aortic valve stenosis: a systematic review and metaanalysis. Cardiovasc Revasc Med. 2018;19(7 Pt B):859-67. doi:10.1016/j. carrev.2018.03.015.
22. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced left ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol. 2018;71(12):1313-21. doi:10.1016/j. jacc.2018.01.045.
23. Schymik G, Tzamalis P, Herzberger V, Bergmann J, Bramlage P, Würth A, et al. Transcatheter aortic valve implantation in patients with a reduced left ventricular ejection fraction: a single-centre experience in 2000 patients (TAVIK Registry). Clin Res Cardiol. 2017;106(12):1018-25. doi:10.1007/s00392-017-1151-9.
24. Greason KL, Eleid MF, Nkomo VT, King KS, Williamson EE, Sandhu GS, et al. Predictors of 1-year mortality after transcatheter aortic valve replacement. J Card Surg. 2018;33(5):243-9. doi:10.1111/jocs.13574.
25. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION (percutaneous coronary intervention prior to transcatheter aortic valve implantation): a randomized clinical trial. JACC Cardiovasc Interv. 2021;14(18):1965-74. doi:10.1016/j.jcin.2021.06.041.
Authors’Roles & Responsibilities
AA = Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
AM = Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
OF = Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
NS = Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
Article receive on Saturday, December 17, 2022
Article accepted on Tuesday, April 18, 2023
All scientific articles published at rbccv.org are licensed under a Creative Commons license
All rights reserved 2017 / © 2024 Brazilian Society of Cardiovascular Surgery
DEVELOPMENT BY 
English PDF
Print
Send this article by email
How to cite this article
Submit a comment
Mendeley
Pocket
Share on Facebook
Share on Twitter